High neutrophil‐to‐lymphocyte ratio predicts poor clinical outcome in patients with castration‐resistant prostate cancer treated with docetaxel chemotherapy

Yao, Akihisa; Sejima, Takehiro; Iwamoto, Hideto; Masago, Toshihiko; Morizane, Shuichi; Honda, Masashi; Takenaka, Atsushi

doi:10.1111/iju.12839

Cited by 24 publications

(29 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After full text assessment, 11 studies did not evaluate the relationship between NLR and survival separately, or failed to report the key data (HR, 95% CI, or P value). Thus, 14 studies with 16,598 PCa patients, 12,19–31 which met our selection criterion, were eventually included in our research. They were all of high quality for our analysis by meta-analysis of observational studies in epidemiology assessment.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer

Yin

Xiao

et al. 2016

Medicine

View full text Add to dashboard Cite

Inflammation is increasingly reported to be associated with the prognosis of patients with cancers. And the prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with prostate cancer (PCa) remains inconsistent. Therefore, we conducted this systematic review and meta-analysis to obtain a more reliable assessment of prognostic significance of NLR in PCa.A comprehensive literature research regarding the association of NLR and prognosis of PCa was performed through PubMed, Embase, Cochrane Central, and Web of Science. The hazard ratios (HRs) and its 95% confidence intervals (CIs) for overall survival (OS), progression-free survival, or recurrence-free survival were extracted and pooled using fix-effects model or random-effects model.A total of 14 studies that met our criterion were included in this meta-analysis. Our pooled results demonstrated that elevated NLR was not significantly associated with the poor OS (HR = 1.45; 95% CI 0.77–2.71; P = 0.248) or recurrence-free survival (HR = 1.34; 95% CI 0.89–2.02; P = 0.155) of patients with localized PCa. Although elevated NLR predicted poorer OS (HR = 1.57; 95% CI 1.41–1.74; P < 0.001) and progression-free survival (HR = 1.97; 95% CI 1.28–3.04; P = 0.002) of patients with metastatic castration resistant prostate cancer (mCRPC).Elevated NLR is a strong indicator of poorer prognosis of patients with mCRPC, whereas the NLR is not significantly associated with prognosis of patients with localized PCa. Therefore, NLR could be used in patients with mCRPC for risk stratification and decision making of individual treatment.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer

Yin

Xiao

et al. 2016

Medicine

View full text Add to dashboard Cite

show abstract

“…A summary of 15 recent studies investigating the prognostic role of NLR in PC is shown in Table . Six studies investigated the prognostic value of NLR in patients who underwent radical prostatectomy for PC; five studies evaluated the preoperative value, and the remaining studies evaluated postoperative values.…”

Section: Differential Blood Cell Markersmentioning

confidence: 99%

“…The cut‐off value for high versus low NLR varied from 3 to 5. Six studies showed that high pretreatment NLR was associated with poor survival in patients who received docetaxel chemotherapy for mCRPC . In addition to the role of pretreatment NLR, Lorente et al .…”

Section: Differential Blood Cell Markersmentioning

confidence: 99%

“…A summary of 15 recent studies investigating the prognostic role of NLR in PC is shown in Table 12. 76,88,[129][130][131][132][133][134][135][136][137][138][139][140][141] Six studies investigated the prognostic value of NLR in patients who underwent radical prostatectomy for PC; five studies evaluated the preoperative value, and the remaining studies evaluated postoperative values. The outcomes of those studies included survival (BCRFS, CSS and OS), as well as pathological results.…”

Section: Nlr In Pcmentioning

confidence: 99%

See 1 more Smart Citation

Role of systemic inflammatory response markers in urological malignancy

Ohno

2018

Int J of Urology

View full text Add to dashboard Cite

The systemic inflammatory response is associated with survival in patients with a variety of cancers. This inflammatory response is measured in the peripheral blood, and can be monitored using two categories of indices: concentration of specific serum proteins (albumin, C‐reactive protein) and differential blood cell count (neutrophils, lymphocytes and platelets). Furthermore, combinations of these indices, such as the Glasgow Prognostic Score, which consists of the serum C‐reactive protein and albumin level; the neutrophil‐to‐lymphocyte ratio; the platelet‐to‐lymphocyte ratio; and the prognostic nutritional index, which is based on peripheral blood lymphocyte count and serum albumin level, have also been evaluated and compared in cancer research. To date, there are hundreds of studies that have shown the prognostic value of systemic inflammatory response markers in patients with urological cancer. Most studies have evaluated the prognostic and predictive role of the pretreatment value of the markers, although some have focused on the role of the post‐treatment value at specific points during the clinical course. The advantages of systemic inflammatory response markers are that they are easily measurable and inexpensive in the clinical setting. However, it is important to consider how clinicians use these markers in clinical practice. The present review provides a concise overview regarding systemic inflammatory markers in urological cancers, specifically C‐reactive protein, Glasgow Prognostic Score/modified Glasgow Prognostic Score, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio and prognostic nutritional index.

show abstract

“…The neutrophil-to-lymphocyte ratio (NLR) is one factor that has been widely reported to be a prognostic factor not only in prostate cancer but also in some solid cancers (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). In addition, the NLR can be calculated easily from routine complete blood counts (CBCs) in peripheral blood samples (4,5).…”

Section: Introductionmentioning

confidence: 99%

Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate

et al. 2018

View full text Add to dashboard Cite

Abstract. Abiraterone acetate (AA), a CYP17 inhibitor, now has a crucial role in the treatment of castration-resistant prostate cancer (CRPC), and previous studies have reported several prognostic clinical factors for AA treatment. The neutrophil-to-lymphocyte ratio (NLR) has also been investigated for a CRPC treatments in a few reports, however it has not been identified to be a prognostic factor for AA treatment in Japanese patients. The present study aimed to assess the association of the baseline NLR with the overall survival (OS) in CPRC patients treated by AA. The present study retrospectively reviewed a total of 90 consecutive patients with CRPC treated with AA from 2011 to 2016 at

show abstract

High neutrophil‐to‐lymphocyte ratio predicts poor clinical outcome in patients with castration‐resistant prostate cancer treated with docetaxel chemotherapy

Cited by 24 publications

References 25 publications

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer

Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer

Role of systemic inflammatory response markers in urological malignancy

Baseline neutrophil‑to‑lymphocyte ratio predicts the prognosis of castration‑resistant prostate cancer treated with abiraterone acetate

Contact Info

Product

Resources

About